For the year ending 2025-12-31, ELDN has $169,009K in assets. $32,230K in debts. $22,808K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 22,808 | 20,549 | ||
| Short-term investments | 110,528 | 119,629 | ||
| Prepaid expenses and other current assets | 2,352 | 3,552 | ||
| Total current assets | 135,688 | 143,730 | ||
| Operating lease right-of-use asset, net | 613 | 926 | ||
| In-process research and development | 32,386 | 32,386 | ||
| Other assets | 322 | 363 | ||
| Total assets | 169,009 | 177,405 | ||
| Accounts payable | 3,627 | 5,833 | ||
| Current operating lease liability | 358 | 314 | ||
| Accrued expenses and other liabilities | 14,359 | 5,430 | ||
| Total current liabilities | 18,344 | 11,577 | ||
| Deferred tax liability | 2,187 | 2,183 | ||
| Non-current operating lease liability | 283 | 640 | ||
| Warrant liabilities | 11,416 | 44,865 | ||
| Total liabilities | 32,230 | 59,265 | ||
| Convertible preferred stock, value-Series XNon Voting Convertible Preferred Stock | 2,151 | 2,151 | ||
| Convertible preferred stock, value-Series X1Non Voting Convertible Preferred Stock | 53,543 | 53,543 | ||
| Common stock, 0.001 par value, 300,000,000 and 200,000,000 shares authorized at december 31, 2025 and 2024, respectively 75,430,033 and 59,789,275 shares issued and outstanding at december 31, 2025 and 2024, respectively | 75 | 60 | ||
| Additional paid-in capital | 482,189 | 417,946 | ||
| Accumulated other comprehensive income | 24 | 26 | ||
| Accumulated deficit | -401,203 | -355,586 | ||
| Total stockholders' equity | 81,085 | 62,446 | ||
| Total liabilities, convertible preferred stock and stockholders' equity | 169,009 | 177,405 | ||
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)